Search

Displaying results 1881 - 1890 of 10000 in total
  1. Drug

    Calcitriol

    go.drugbank.com/drugs/DB00136
    ApprovedInvestigationalNutraceutical

    to [DB00146] in the liver and kidneys. … tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system.

    Synonyms: (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol, (1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triolProducts: ROCALTROL CAPSULAS DE GELATINA BLANDA0.25MCG, ROCALTROL® 0.50 CÁPSULAS DE GELATINA BLANDA 0.50 MCG.
  2. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]

  3. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    In gout patients treated with pegloticase, the conversion of uric acid to allantoin leads to lower plasma uric acid concentrations. … [L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425]

  5. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist.

    Categories: Thyroid Hormone Receptor beta Agonist, Thyroid hormone receptor-beta (THR-beta) agonist
  6. Drug

    Citric acid

    go.drugbank.com/drugs/DB04272
    ApprovedInvestigationalNutraceuticalVet approved

    The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. … Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.

    Mixtures: E-Z-gas II, Sal de Uvas PicotProducts: bdr Re-action natural low base skin refiner exfoliation essence
  7. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  8. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary … circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.

    Categories: Prostacyclin Receptor Agonist, Prostacyclin Receptor Agonists
  9. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    Organophosphates bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme. … If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase

  10. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as … efficacious than [vedolizumab] and without the CNS effects of [natalizumab].

    Categories: Integrin Receptor Antagonist